Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C172H278N24O55 |
Molecular Weight | 3562.1755 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 16 / 16 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC3=CNC4=NC=CC=C34)NC(=O)[C@H](CC5=CC=C(O)C=C5)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)N(C)C(=O)[C@@H]6CC(=O)NCCCC[C@H](NC(C)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC7=CC=CC=C7)C(=O)N6)C(C)(C)C)C8CCCCC8)C(O)=O)C(O)=O
InChI
InChIKey=JDXCOXKBIGBZSK-PSNKNOTQSA-N
InChI=1S/C172H278N24O55/c1-9-10-11-12-13-14-15-16-17-18-19-20-27-44-146(202)182-136(170(226)227)53-56-144(200)177-64-67-229-69-71-231-73-75-233-77-79-235-81-83-237-85-87-239-89-91-241-93-95-243-97-99-245-101-103-247-105-107-249-109-111-251-113-112-250-110-108-248-106-104-246-102-100-244-98-96-242-94-92-240-90-88-238-86-84-236-82-80-234-78-76-232-74-72-230-70-68-228-66-59-145(201)175-60-31-29-41-135(169(224)225)186-165(220)152(126-37-25-22-26-38-126)193-162(217)142-43-34-65-196(142)168(223)140(116-125-47-51-129(199)52-48-125)190-157(212)133(54-57-148(204)205)184-161(216)139(117-127-120-180-154-130(127)39-32-62-178-154)188-159(214)138(115-124-45-49-128(198)50-46-124)189-166(221)153(172(5,6)7)194-163(218)143(119-150(208)209)195(8)167(222)141-118-147(203)176-61-30-28-40-131(181-122(4)197)158(213)192-151(121(2)3)164(219)185-134(55-58-149(206)207)156(211)183-132(42-33-63-179-171(173)174)155(210)187-137(160(215)191-141)114-123-35-23-21-24-36-123/h21,23-24,32,35-36,39,45-52,62,120-121,126,131-143,151-153,198-199H,9-20,22,25-31,33-34,37-38,40-44,53-61,63-119H2,1-8H3,(H,175,201)(H,176,203)(H,177,200)(H,178,180)(H,181,197)(H,182,202)(H,183,211)(H,184,216)(H,185,219)(H,186,220)(H,187,210)(H,188,214)(H,189,221)(H,190,212)(H,191,215)(H,192,213)(H,193,217)(H,194,218)(H,204,205)(H,206,207)(H,208,209)(H,224,225)(H,226,227)(H4,173,174,179)/t131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,151-,152-,153+/m0/s1
Molecular Formula | C172H278N24O55 |
Molecular Weight | 3562.1755 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 16 / 16 |
E/Z Centers | 10 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:19:18 GMT 2023
by
admin
on
Fri Dec 15 19:19:18 GMT 2023
|
Record UNII |
YG391PK0CC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
589717
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
||
|
FDA ORPHAN DRUG |
699319
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID301336930
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY | |||
|
Zilucoplan
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY | |||
|
YG391PK0CC
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY | |||
|
SUB194709
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY | |||
|
100000181198
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY | |||
|
YG391PK0CC
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY | |||
|
DB15636
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY | |||
|
10602
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY | |||
|
GH-30
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY | |||
|
1841136-73-9
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY | |||
|
C147518
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY | |||
|
133083018
Created by
admin on Fri Dec 15 19:19:18 GMT 2023 , Edited by admin on Fri Dec 15 19:19:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
In vitro studies also demonstrated that RA101495 is capable of preventing MAC assembly after thrombin mediated complement activation and is a potent disruptor of the interaction in between C5b and C6.
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
BLOCKS C5 CONVERTASE FROM CONVERTING C5 TO C5A AND C5B
BINDING
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|